JANUARY 16, 2008


OSU-CHS studies emphysema treatment

Photo of male doctor looking at x-rays.
Dr. Daniel Nader studies X-rays of lung cells affected by emphysema. OSU Center for Health Sciences is one of several national sites evaluating a promising treatment for severe emphysema.

The Center for Respiratory Medicine at Oklahoma State University Center for Health Sciences is participating as a clinical trial site evaluating an implanted device for the treatment of severe emphysema, the IBV® Valve System, and implanted the device in the first three patients to participate in the national trial.

Safety and effectiveness data from the IBV® Valve Trial will be submitted to the U.S. Food and Drug Administration (FDA) for approval to market the device in the United States. The IBV® Valve System was developed and is manufactured by Spiration Inc., of Redmond, Wash.

“We are excited about this opportunity for eligible emphysema patients in northeastern Oklahoma to experience this revolutionary new device that could ultimately ease their suffering,” said Daniel Nader, D.O., director of the OSU Center for Respiratory Medicine and clinical assistant professor of internal medicine.

More than three million Americans are living with emphysema, a condition that is chronic and severely impacts quality of life. People with severe emphysema struggle with each breath and therefore cannot do very simple things, like simultaneously walking and talking, that most people take for granted. Many do not respond well to current medical treatments or are not eligible for major surgery such as lung volume reduction or lung transplantation. The IBV® Valve System, which is much less invasive than surgery, may one day offer a new treatment option to improve the quality of life for these patients.

The OSU Center for Respiratory Medicine is actively recruiting patients for the trial. The study is open to men and women age 40 to 74 who have been diagnosed with predominantly upper lobe emphysema and severe dyspnea (shortness of breath). Eligible patients must also be able to participate in pulmonary function and standardized exercise tests, have not smoked for four months and are willing to not smoke during the trial. Volunteers must be willing to be assigned randomly to one of two groups: One group will receive the IBV® Valve System while the other group will serve as a control group and will not receive the IBV® Valve System. Additional criteria must be met for participation in the study. For information about the trial and to see if a patient is qualified to participate call the toll-free number (877) 547-8839 or visit www.emphysematrial.com.